计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S613390-5mg |
5mg |
期货 ![]() |
| |
| S613390-25mg |
25mg |
期货 ![]() |
|
| 别名 | 沙比沙布林 |
|---|---|
| 英文别名 | UNII-37L1JX37J5 | 1332881-26-1 | WQGVHOVEXMOLOK-UHFFFAOYSA-N | (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone | AKOS040742814 | Sabizabulin | SABIZABULIN [USAN] | SABIZABULIN [WHO-DD] | S6772 | SCHEMBL724794 | SABIZABULIN [INN] | [2 |
| 规格或纯度 | Moligand™ |
| 英文名称 | sabizabulin |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| EC号 | 889-539-8 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | [2-(1H-indol-3-yl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone |
| INCHI | 1S/C21H19N3O4/c1-26-17-8-12(9-18(27-2)20(17)28-3)19(25)16-11-23-21(24-16)14-10-22-15-7-5-4-6-13(14)15/h4-11,22H,1-3H3,(H,23,24) |
| InChi Key | WQGVHOVEXMOLOK-UHFFFAOYSA-N |
| Smiles | COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43 |
| Isomeric SMILES | COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43 |
| 关联CAS | 1332881-26-1 |
| PubChem CID | 53379371 |
| MeSH Entry Terms | (2-(1H-indol-3-yl)-1H-imidazol-5-yl)-(3,4,5-trimethoxyphenyl)methanone;methanone, (2-(1H-indol-3-yl)-1H-imidazol-5-yl)(3,4,5-trimethoxyphenyl)-;sabizabulin;VERU-111 |
| 分子量 | 377.400 g/mol |
|---|---|
| XLogP3 | 3.400 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 377.138 Da |
| 单同位素质量Monoisotopic Mass | 377.138 Da |
| 拓扑极表面积Topological Polar Surface Area | 89.200 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 534.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD et al.. (2018) Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.. J Med Chem, 61 (17): (7877-7891). [PMID:30122035] |
| 2. Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W et al.. (2019) Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.. J Exp Clin Cancer Res, 38 (1): (29). [PMID:30674344] |